OCX - Oncocyte Corporation
Previous close
3.1427
0 0%
Share volume: 8,688
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.14
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-10 | 2023-04-12 | 2023-05-15 | 2023-08-10 | 2023-11-09 | 2024-04-16 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 171.051 M | 157.344 M | 100.091 M | 82.800 M | 87.540 M | 81.587 M | 74.892 M | 70.973 M | |
| Current Assets | 49.368 M | 36.636 M | 25.536 M | 15.648 M | 20.984 M | 16.917 M | 10.698 M | 6.535 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.151 M | 2.174 M | 977.000 K | 970.000 K | 1.179 M | 672.000 K | 643.000 K | 735.000 K | |
| Short Term Investments | 2.151 M | 2.174 M | 977.000 K | 970.000 K | 1.179 M | 672.000 K | 643.000 K | 735.000 K | |
| Total Receivables | 1.802 M | 1.990 M | 2.012 M | 1.901 M | 1.716 M | 1.882 M | 484.000 K | 161.000 K | |
| Current Cash | 45.415 M | 32.472 M | 20.426 M | 12.356 M | 17.898 M | 14.224 M | 9.432 M | 5.578 M | |
| Total Non-current Assets | 121.683 M | 120.708 M | 74.555 M | 67.152 M | 66.556 M | 64.670 M | 64.194 M | 64.438 M | |
| Property Plant Equipment | 9.087 M | 9.256 M | 8.763 M | 6.403 M | 5.997 M | 4.076 M | 3.799 M | 3.528 M | |
| Other Assets | 2.871 M | 2.703 M | 2.459 M | 2.388 M | 2.220 M | 2.277 M | 2.100 M | 2.637 M | |
| Intangible Assets | 89.341 M | 88.365 M | 61.633 M | 56.661 M | 56.639 M | 56.617 M | 56.595 M | 56.573 M | |
| Goodwill | 18.684 M | 18.684 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 171.051 M | 157.344 M | 100.091 M | 82.800 M | 87.540 M | 81.587 M | 74.892 M | 70.973 M | |
| Total liabilities | 82.954 M | 75.411 M | 60.497 M | 39.335 M | 39.215 M | 39.102 M | 49.298 M | 54.053 M | |
| Total current liabilities | 14.154 M | 12.952 M | 12.106 M | 9.430 M | 7.667 M | 8.033 M | 7.194 M | 8.327 M | |
| Accounts Payable | 2.465 M | 1.826 M | 1.253 M | 1.395 M | 875.000 K | 1.136 M | 953.000 K | 908.000 K | |
| Other liabilities | 65.666 M | 59.524 M | 45.662 M | 27.355 M | 29.150 M | 28.715 M | 39.900 M | 43.212 M | |
| Current long term debt | 1.413 M | 827.000 K | 815.000 K | 775.000 K | 737.000 K | 720.000 K | 665.000 K | 821.000 K | |
| Long term debt | 3.134 M | 2.935 M | 2.729 M | 2.550 M | 2.398 M | 2.354 M | 2.204 M | 2.514 M | |
| Other liabilities | 65.666 M | 59.524 M | 45.662 M | 27.355 M | 29.150 M | 28.715 M | 39.900 M | 43.212 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 88.097 M | 81.933 M | 39.594 M | 43.465 M | 48.325 M | 42.485 M | 25.594 M | 16.920 M | |
| Common stock | 5.652 M | 5.931 M | 5.965 M | 5.958 M | 8.566 M | 8.256 M | 7.825 M | 8.264 M | |
| Retained earnings | -206.437 M | -215.698 M | -260.676 M | -257.643 M | -265.976 M | -272.465 M | -289.876 M | -299.005 M |